OncRef

Clinical Trial: NCT03589547

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

Status:

COMPLETED

Phase:

Phase 2

Lead Sponsor:Brown University
Information Provided By:Brown University
Last Update Posted:2026-04-02

Study Overview

Brief Summary

Durvalumab is a drug that stimulates the immune system to fight lung cancer. Durvalumab is FDA approved to treat lung cancer. Stereotactic body radiation therapy (SBRT) is a newer radiation treatment that gives fewer, but higher doses of radiation than standard radiation.

With SBRT, radiation is focused toward the cancer and away from normal surrounding lung tissue. It is possible that when cancer cells are damaged by SBRT Durvalumab may be more effective in activating the immune system. SBRT is a standard FDA approved treatment for early stage (stage 1) lung cancer and is investigational in patients such as yourself with stage 3 lung cancer. The combination of Durvalumab and SBRT is investigational. This study will investigate the effects, good and bad, of the combination of Durvalumab and SBRT.

Official Title

Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung

Conditions

Stage III Non-small-cell Lung Cancer

Intervention / Treatment

  • Drug: Durvalumab
  • Radiation: SBRT

Other Study ID Numbers

  • BrUOG 358

Start Date (Actual)

2019-05-13

Primary Completion Date (Actual)

2024-01-31

Study Completion Date (Actual)

2026-02-18

Enrollment (Actual)

11

Study Type

Interventional

Phase

Phase 2